Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

Avacta Group plc. (10/10/18). "Press Release: Avacta Agrees Affimer Reagent Licensing Deal with New England Biolabs (NEB)". Edinburgh & Glasgow.

Organisation Organisation Avacta Group plc (AIM: AVCT)
  Group Avacta (Group)
Products Product reagents (bio/biochemical)
  Product 2 molecular biology

Royalty bearing license agreement to commercialise a product incorporating the Affimer technology

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a commercial license with New England Biolabs® (NEB®) (Ipswich MA, USA), a global leader in the discovery and production of enzymes for molecular biology applications, to commercialise a product using the Affimer technology for use in both life science research and diagnostics assays.

Avacta and NEB have been collaborating to develop Affimers to combine with NEB's reagents. Avacta has identified Affimers that specifically inhibit certain NEB proprietary enzymes to provide modulation of their activity in response to temperature. Unlike alternative enzyme inhibitors, Affimers can be fine-tuned to switch at the right temperature without having a negative effect on the overall assay performance. NEB is in the final stages of product testing and the two companies have agreed terms under which NEB will commercialise the combined product.

Financial details of the agreement are not being disclosed, but Avacta will receive a royalty on product sales, which may occur as soon as 2019.

NEB and Avacta expect to continue the collaboration to generate Affimer tools and inhibitors to other enzymes, enabling further product developments.

Alastair Smith, Chief Executive of Avacta Group commented:

"We are delighted that the collaboration with New England Biolabs, a highly respected, globally recognized leader in the life sciences reagents market, has resulted in this commercial agreement to incorporate the Affimer technology into one of their products.

This is another important milestone for Avacta, because it further validates the Affimer technology and our licensing business model. We have built a pipeline of evaluations and collaborations, such as this one with New England Biolabs, to deliver numerous license agreements to commercialise Affimer-based products. Collectively, these royalty bearing licenses will underpin the future high margin revenue from Affimer reagents.

We are looking forward to continuing our collaboration to generate more combined products for the research and molecular diagnostic markets.

This is a very exciting time for the Group and we look forward to updating the market on continuing commercial progress for Affimer reagents and, importantly, on therapeutic licensing deals."


Wetherby site

Unit 20, Ash Way
Thorp Arch Estate, Wetherby
LS23 7FA
+44 (0)1904 21 7070 Affimers (link is external)

Cambridge site

Unit B, 1 Lion Works, Station Road East
Whittlesford, Cambridge
CB22 4WL
+44 (0)1223 75 0353 Affimers (link is external)

Investor relations
Yellow Jersey PR
1st floor, 30 Stamford Street
+44 (0)7764 947 137
@yellowjerseypr (link is external)

Record changed: 2018-10-15


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Avacta (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

» top